ArriVent BioPharma, Inc.
Public company- Headquarters
- NEWTOWN SQUARE, Pennsylvania
- Ticker
- AVBP
- CIK
- 0001868279
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| President, Research and DevelopmentStuart Lutzker, M.D., Ph.D. | Nov 9, 2026 | Departed |
| leading the Company’s research and development functionPriti Patel, M.D. | Nov 9, 2026 | Role change |
Related companies
Same industry and state, with recent events.
- MADRIGAL PHARMACEUTICALS, INC.
Class II director appointed: John C. Reed, M.D., Ph.D.
- GeoVax Labs, Inc.
director appointed: Shahin Behroyan
- BRISTOL MYERS SQUIBB CO
WARN notice: Princeton, NJ
- JOHNSON & JOHNSON
WARN notice: New Brunswick, NJ
- Executive departure
President, Research and Development departs: Stuart Lutzker, M.D., Ph.D.
Stuart Lutzker, M.D., Ph.D., President, Research and Development of ArriVent BioPharma, Inc., retires the role, effective December 1, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Nov 9, 2026Role: President, Research and Development
- Role change
leading the Company’s research and development function role change: Priti Patel, M.D.
Priti Patel, M.D. moved to leading the Company’s research and development function at ArriVent BioPharma, Inc., effective December 1, 2026. Priti Patel, M.D. succeeds Stuart Lutzker, M.D., Ph.D.. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Nov 9, 2026Role: leading the Company’s research and development function
Last verified Nov 10, 2026